<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392340</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000508641</org_study_id>
    <secondary_id>CCLG-NB-2006-05</secondary_id>
    <secondary_id>EUDRACT-2005-000915-80</secondary_id>
    <secondary_id>EU-20641</secondary_id>
    <nct_id>NCT00392340</nct_id>
  </id_info>
  <brief_title>Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma</brief_title>
  <official_title>An Open-Label, Multicentre, Phase II Study of TVD as Treatment for Children With Stage 4 Neuroblastoma Failing to Respond to First-Line Treatment According to HR-NBL-01/ E-SIOP [Topotecan-Vincristine-Doxorubicin in Children With Stage 4 Neuroblastoma Failing to Respond to COJEC (TVD)]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as topotecan, vincristine, and doxorubicin, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving topotecan together with vincristine&#xD;
      and doxorubicin works in treating young patients with refractory stage 4 neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess whether treatment with topotecan hydrochloride, vincristine, and doxorubicin&#xD;
           hydrochloride can achieve a satisfactory response rate in pediatric patients with stage&#xD;
           4 neuroblastoma that failed to respond to rapid first-line treatment.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine time to progression in these patients.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open-label study.&#xD;
&#xD;
      Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 and vincristine IV&#xD;
      continuously and doxorubicin hydrochloride IV continuously over 48 hours on days 5 and 6.&#xD;
      Patients also receive filgrastim (G-CSF) subcutaneously beginning on day 9 and continuing&#xD;
      until blood counts recover. Treatment repeats every 21-28 days for 2 courses in the absence&#xD;
      of disease progression or unacceptable toxicity. Patients who achieve partial response (PR)&#xD;
      after two courses of treatment receive an additional two courses. Patients who achieve&#xD;
      complete response or very good PR are treated according to the standard therapy in protocol&#xD;
      SIOP-EUROPE- HR-NBL-1. Patients who fail to achieve PR after 2 courses receive further&#xD;
      treatment at the physician's discretion.&#xD;
&#xD;
      Patients are followed periodically for at least 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 63 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (complete or partial) &gt; 50% after 2 courses of topotecan hydrochloride, vincristine, and doxorubicin hydrochloride</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at the time of local progression or relapse, progression of pre-existing metastases, metastatic relapse, second primary malignancy, or death from any cause</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and incidence of adverse events</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of stage 4 neuroblastoma&#xD;
&#xD;
          -  Failed to achieve adequate metastatic partial response after first-line therapy while&#xD;
             enrolled on protocol SIOP-EUROPE-HR-NBL-1&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Neutrophil count &gt; 1,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Creatinine ≤ 1.36 mg/dL&#xD;
&#xD;
          -  Bilirubin ≤ 2.92 mg/dL&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times upper limit of normal&#xD;
&#xD;
          -  Glomerular filtration rate ≥ 60 mL/min&#xD;
&#xD;
          -  Normal cardiac function on echocardiography&#xD;
&#xD;
          -  No severe organ dysfunction&#xD;
&#xD;
          -  No active hepatitis C or hepatitis B virus positivity&#xD;
&#xD;
          -  No HIV infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No anti-tumor chemotherapy within the past 10 days&#xD;
&#xD;
          -  No radiotherapy within the past 30 days&#xD;
&#xD;
          -  No other investigational drugs within the past 30 days&#xD;
&#xD;
          -  No prior doxorubicin hydrochloride&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Makin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Manchester Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Child Health at University of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health at Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Ireland</country>
  </removed_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

